ESR1 was the main target of most FDA approved drugs (represented by yellow hexagon) in the network, providing a molecular basis for potential clinical applications of naringenin to treat prostate cancer targeting ESR1. This evidence concerns the gene ESR1 and Familial prostate cancer.